Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The science of sustainable fat loss and GLP-1 therapy
That said, $171 per month is still competitive in the compounded GLP-1 market, particularly compared to providers charging $200-300 per month for equivalent formulations
The GLP-1 Revolution Driving Growth Lilly dominates the obesity and diabetes market with two blockbuster drugs that are rewriting treatment paradigms: Mounjaro (Type 2 Diabetes) + Zepbound (Obesity) = $10.1B in Q3 2025 revenues (+131% YoY) Mounjaro: $6.52B (+109% YoY) Zepbound: $3.59B (+184% YoY) For context: This tirzepatide franchise just surpassed Merck's Keytruda ($8.1B in Q3) to become the world's best-selling drug
Do I need to follow a strict diet while using Levia
US$ 29.20
US$ 28.70
US$ 22.06
US$ 29.32
US$ 24.13
US$ 26.88
